Henry Schein (HSIC) AI Stock Analysis

• Market Cap: $8.59B
• Dividend Yield: N/A
• Average Volume (3M): 1.57M
• Price to Earnings (P/E): 21.9
• Beta (1Y): 0.38
• Revenue Growth: 1.75%
• EPS Growth: 8.76%
• Country: US
• Employees: 25,000
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Distribution
• EPS (TTM): 1.15
• Shares Outstanding: 121,719,540
• 10 Day Avg. Volume: 1,756,955
• 30 Day Avg. Volume: 1,572,846
• PEG Ratio: 0.91
• Price to Book (P/B): 2.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.45
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 0.22
• Enterprise Value/Gross Profit: 2.85
• Enterprise Value/Ebitda: 3.03
• 1Y Price Target: $73.88
• Price Target Upside: 4.96% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9

• Rating: 74 Outperform
• Price Target: $79.00 ▲(12.23%Upside)

Henry Schein's overall stock score is driven by its stable financial performance and strategic initiatives, bolstered by recent corporate events. However, modest revenue growth and a valuation without dividend yield slightly limit its attractiveness. Technical indicators suggest neutral momentum, while earnings call insights affirm confidence amid challenges.

Positive Factors

Cost Management

Management's in-flight cost-cutting plan meant that there was room for OpEx management upside, which came through and led to the bottom line outperformance.

Financial Guidance

Management fully affirmed its previous FY/25 financial guidance.

Revenue Growth

KKR’s recent board addition and expertise in the dental ecosystem is likely to lead to opportunities to accelerate revenue growth.

Negative Factors

Consumer Sentiment

There is some uncertainty if worsening consumer sentiment will translate to lower dental spend.

Market Conditions

There is no visible pathway to near-term/medium-term upside in what remains choppy macro conditions for dental as a whole.

Revenue Performance

Total revenue of $3.17 billion fell slightly short of the expectation of $3.21 billion.

Henry Schein Business Overview & Revenue Model

Company Description

Henry Schein, Inc. is a leading global distributor of healthcare products and services to office-based dental and medical practitioners. The company operates in two main sectors: healthcare distribution and technology. It offers a comprehensive range of products, including dental supplies, medical supplies, and equipment, as well as value-added services such as practice management software solutions and consulting services. With a strong global presence and a focus on providing innovative solutions, Henry Schein supports healthcare professionals in delivering quality care to their patients.

How the Company Makes Money

Henry Schein makes money primarily through the distribution of healthcare products and services. The company's revenue model is built on selling dental and medical supplies, equipment, and pharmaceuticals to healthcare practitioners. A significant portion of its revenue comes from the sale of consumables and equipment in the dental and medical segments. Additionally, Henry Schein generates income from technology and value-added services, including practice management software, e-commerce solutions, and consulting services. Key revenue streams include direct sales to healthcare providers and partnerships with manufacturers and suppliers, which enable the company to offer a broad portfolio of products. The company's global reach and strong distribution network contribute significantly to its earnings by ensuring efficient and timely delivery of products to its customers.

Henry Schein Financial Statement Overview

Summary

Henry Schein demonstrates solid financial performance with stable revenue growth and operational efficiency. However, increased debt levels and slight declines in net income are concerns. The company maintains a healthy cash flow position, providing a buffer against potential financial risks.

Income Statement

Henry Schein shows a modest revenue growth with a slight increase in total revenue from $12.34B to $12.67B from 2023 to 2024. The gross profit margin remains steady, but the net income has slightly decreased, impacting the net profit margin negatively. The EBIT and EBITDA margins have shown resilience, indicating stable operational efficiency.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio due to increased debt levels, which could pose a risk if not managed effectively. However, the equity ratio remains healthy, suggesting that the company is maintaining a solid equity base relative to its assets. The return on equity has slightly declined due to reduced net income.

Cash Flow

The company's cash flow statement reveals a strong operating cash flow, which has significantly improved from the previous year, leading to robust free cash flow growth. This improvement indicates effective cash management, although the free cash flow to net income ratio has been under some pressure due to lower net income.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
12.67B	12.34B	12.65B	12.40B	10.12B
	Gross Profit
4.02B	3.86B	3.83B	3.67B	2.81B
	EBIT
621.00M	615.00M	747.00M	851.66M	535.30M
	EBITDA
941.00M	877.00M	1.09B	1.07B	726.81M
	Net Income Common Stockholders
390.00M	416.00M	538.00M	631.00M	403.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
122.00M	171.00M	117.00M	117.97M	421.19M
	Total Assets
10.22B	10.57B	8.61B	8.48B	7.77B
	Total Debt
2.87B	2.74B	1.50B	1.22B	1.00B
	Net Debt
2.75B	2.57B	1.38B	1.10B	581.23M
	Total Liabilities
5.38B	5.42B	3.94B	4.42B	3.79B
	Stockholders Equity
3.39B	3.65B	3.45B	3.43B	3.35B
Cash Flow		Free Cash Flow
661.00M	313.00M	506.00M	630.57M	550.08M
	Operating Cash Flow
848.00M	500.00M	602.00M	709.58M	598.91M
	Investing Cash Flow
-430.00M	-1.14B	-276.00M	-677.22M	-115.02M
	Financing Cash Flow
-510.00M	701.00M	-315.00M	-332.96M	-187.19M

Henry Schein Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 70.39
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSIC, the sentiment is Positive. The current price of 70.39 is below the 20-day moving average (MA) of 70.71, above the 50-day MA of 67.95, and below the 200-day MA of 71.29, indicating a neutral trend. The MACD of 0.95 indicates Positive momentum. The RSI at 52.26 is Neutral, neither overbought nor oversold. The STOCH value of 18.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HSIC.

Henry Schein Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COR	76 Outperform	$56.51B	33.84	161.58%	0.74%	12.18%	-5.92%
MCK	76 Outperform	$90.30B	28.06	51.23%	0.38%	16.22%	15.29%
HSIC	74 Outperform	$8.59B	21.88	11.78%	―	1.75%	8.76%
CAH	68 Neutral	$37.05B	24.24	-43.80%	1.30%	0.78%	183.45%
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
OMI	44 Neutral	$486.50M	―	-49.91%	―	2.84%	-828.91%

Henry Schein Corporate Events

Henry Schein Approves Key Proposals at Annual Meeting

On May 22, 2025, Henry Schein, Inc. held its 2025 Annual Meeting of Stockholders where key proposals were approved, including the election of twelve directors for terms expiring in 2026, and the election of Max Lin and William K. ‘Dan’ Daniel as directors. The meeting also saw the approval of the 2024 compensation for Named Executive Officers and the ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 27, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.

Henry Schein Completes $250M Deal with KKR

On May 16, 2025, Henry Schein, Inc. completed a $250 million strategic investment deal with KKR, making KKR the holder of approximately 12% of Henry Schein’s common shares. This investment is part of a strategic partnership agreement that also led to the appointment of William K. ‘Dan’ Daniel to Henry Schein’s Board of Directors. Daniel, an Executive Advisor at KKR, brings over three decades of leadership experience in the industrial and healthcare sectors. His appointment, alongside Max Lin from KKR, is expected to support Henry Schein’s strategic growth and long-term value creation for stakeholders.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.

Henry Schein Updates Strategic Partnership with KKR

On May 2, 2025, Henry Schein, Inc. and KKR Hawaii Aggregator L.P. entered into a letter agreement to remove KKR’s voting commitment from their Strategic Partnership Agreement, while maintaining all other terms. Additionally, Max Lin was appointed to Henry Schein’s board of directors as an independent director, following the satisfaction of regulatory conditions. Lin, a partner at KKR, will serve on the Nominating and Governance Committee and the Strategic Advisory Committee, bringing extensive experience from his roles in healthcare and private equity.

Henry Schein Adopts New Executive Severance Plan

On April 10, 2025, Henry Schein, Inc. announced the adoption of an Executive Severance Plan and an amended Executive Change in Control Plan. These plans are designed to provide severance benefits to certain executive-level employees under specific circumstances, such as termination without cause or resignation for good reason. The plans include provisions for base salary continuation, pro-rated bonuses, and other benefits, while incorporating restrictive covenants and clawback policies to protect the company’s interests.

Henry Schein Announces Leadership Transition in 2025

On March 11, 2025, Henry Schein, Inc. announced that James P. Breslawski, the company’s President, will transition from his role effective April 1, 2025. He will take on a new position as Senior Advisor while remaining on the Executive Management Committee, signaling a strategic shift in leadership roles within the company.